AbbVie Inc. Debt/Assets

Debt/Assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.

Highlights and Quick Summary

  • Debt/Assets for the quarter ending September 29, 2021 was 54.23% (a -2.31% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Assets decreased by -6.21%
  • Annual Debt/Assets for 2020 was 57.82% (a -23.19% decrease from previous year)
  • Annual Debt/Assets for 2019 was 75.28% (a 10.84% increase from previous year)
  • Annual Debt/Assets for 2018 was 67.92% (a 28.66% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of AbbVie Inc.

Most recent Debt/Assetsof ABBV including historical data for past 10 years.

Interactive Chart of Debt/Assets of AbbVie Inc.

AbbVie Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 54.23% 55.51% 56.83%
2020 57.82% 58.19% 58.47% 73.52% 57.82%
2019 74.88% 64.61% 65.21% 65.43% 75.28%
2018 67.92% 61.22% 60.2% 53.77% 67.92%
2017 52.79% 54.9% 55.58% 56.27% 52.79%
2016 55.74% 56.0% 56.31% 59.41% 55.74%
2015 59.7% 58.59% 57.79% 57.2% 59.7%
2014 54.44% 51.99% 50.75% 50.27% 54.44%
2013 50.42% 52.42% 52.88% 55.35% 50.42%
2012 58.03% 0.0% 0.0% 0.0% 58.03%
2011 0.25% 0.0% 0.0% 0.0% 0.25%
2010 0.0% 0.0%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.